Iyo M, Maeda Y, Inada T, Kitao Y, Sasaki H, Fukui S
Division of Drug Dependence and Psychotropic Drugs Clinical Research, National Institute of Mental Health, National Center of Neurology and Psychiatry, Chiba, Japan.
Neuropsychopharmacology. 1995 Aug;13(1):33-9. doi: 10.1016/0893-133X(94)00133-K.
The effects of rolipram, a selective cAMP phosphodiesterase inhibitor, on locomotor activity, rearing, and stereotyped behavior (sniffing, repetitive head movements) induced by methamphetamine (MAP) over 1 hour were investigated in rats. Coadministration of rolipram (4 mg/kg IP) significantly attenuated the responses of locomotor activity, rearing and repetitive head movements to MAP (2,4 or 8 mg/kg IP). Rolipram (0.5, 1, 2, or 4 mg/kg IP) dose-dependently inhibited locomotor hyperactivity and rearing induced by 4 mg/kg of MAP. The rearing was completely inhibited by 4 mg/kg of rolipram, whereas the maximal inhibition of the locomotor hyperactivity was about 50%. However, rolipram did not alter MAP-induced sniffing and repetitive head movements. These results indicate that there is heterogeneity in the response of MAP-induced behavior to rolipram, suggesting that MAP-induced behavioral alteration may be partly regulated by cAMP levels in the brain.
在大鼠中研究了选择性环磷腺苷磷酸二酯酶抑制剂咯利普兰对甲基苯丙胺（MAP）诱导的1小时运动活动、竖毛行为和刻板行为（嗅探、重复性头部运动）的影响。咯利普兰（4mg/kg腹腔注射）与MAP（2、4或8mg/kg腹腔注射）联合给药显著减弱了运动活动、竖毛行为和重复性头部运动对MAP的反应。咯利普兰（0.5、1、2或4mg/kg腹腔注射）剂量依赖性地抑制了4mg/kg MAP诱导的运动性多动和竖毛行为。4mg/kg咯利普兰完全抑制了竖毛行为，而对运动性多动的最大抑制约为50%。然而，咯利普兰并未改变MAP诱导的嗅探和重复性头部运动。这些结果表明，MAP诱导的行为对咯利普兰的反应存在异质性，提示MAP诱导的行为改变可能部分受大脑中环磷腺苷水平的调节。
